There’s been a lot of discussion lately about compounding pharmacies stopping tirz production mid-stream, with prescriptions transferred automatically to a different facility. Most of the conversation has been about logistics: will the new supply arrive on time, will the dose match, will the beyond-use date hold. What’s getting less attention is the formulation question. A rx transfer from one 503B to another isn’t a continuity event; it’s a new product. The excipient profile may differ. The buffer system may differ. The concentration and injection volume may differ. The sterility testing cycle restarts from whatever that pharmacy’s lot cadence is. I’m not saying the new pharmacy is worse. I genuinely don’t know. But treating it as equivalent to the original formulation before asking those questions is the part that bothers me. The CoA from pharmacy A doesn’t transfer. You’re drawing a new probabilistic inference abt a new lot from a facility whose process you haven’t evaluated. The loyalty most people have to their original compounder isn’t irrational; it’s at least partly earned through exposure. Starting fresh with a new source mid-titration means the two sources are now confounded in any outcome you’re tracking. Worth naming before you adjust the dose based on a response that might partly be formulation-driven.